Comparing InMed Pharmaceuticals (NASDAQ:INM) and Zhengye Biotechnology (NASDAQ:ZYBT)

InMed Pharmaceuticals (NASDAQ:INM) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Profitability

This table compares InMed Pharmaceuticals and Zhengye Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Zhengye Biotechnology	N/A	N/A	N/A

Risk and Volatility

InMed Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Zhengye Biotechnology has a beta of -2.56, suggesting that its stock price is 356% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for InMed Pharmaceuticals and Zhengye Biotechnology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1	0	0	0	1.00
Zhengye Biotechnology	1	0	0	0	1.00

Valuation & Earnings

This table compares InMed Pharmaceuticals and Zhengye Biotechnology”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94 million	0.89	-$8.16 million	($2.89)	-0.46
Zhengye Biotechnology	$16.64 million	4.64	-$9.98 million	N/A	N/A

InMed Pharmaceuticals has higher earnings, but lower revenue than Zhengye Biotechnology.

Insider & Institutional Ownership

20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 0.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Zhengye Biotechnology beats InMed Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.